Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Other Non-Current Assets (2016 - 2026)

United Therapeutics' Other Non-Current Assets history spans 17 years, with the latest figure at $196.9 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 11.35% to $196.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $196.9 million, a 11.35% decrease, with the full-year FY2025 number at $196.9 million, down 11.35% from a year prior.
  • Other Non-Current Assets hit $196.9 million in Q4 2025 for United Therapeutics, down from $262.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for UTHR hit a ceiling of $262.6 million in Q3 2025 and a floor of $105.8 million in Q2 2022.
  • Historically, Other Non-Current Assets has averaged $161.2 million across 5 years, with a median of $159.8 million in 2023.
  • Biggest five-year swings in Other Non-Current Assets: crashed 40.23% in 2022 and later skyrocketed 46.31% in 2024.
  • Tracing UTHR's Other Non-Current Assets over 5 years: stood at $108.2 million in 2021, then increased by 5.64% to $114.3 million in 2022, then skyrocketed by 32.81% to $151.8 million in 2023, then skyrocketed by 46.31% to $222.1 million in 2024, then dropped by 11.35% to $196.9 million in 2025.
  • Business Quant data shows Other Non-Current Assets for UTHR at $196.9 million in Q4 2025, $262.6 million in Q3 2025, and $233.3 million in Q2 2025.